Micheline R Kergoat

This inventor holds 25 USPTO granted patents, plus 2 CIPO patents and 10 EPO patents, primarily in Diabetes Treatment. Top assignees: Merck Patent Gmbh, Merck Patent Gesellschaft MIT Beschrankter Haftung, Metabrain Research. Active years: 2000-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Micheline R Kergoat. Retrieved from https://idiyas.com/inventor/micheline-r-kergoat

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25

% Patents Active = 76.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 8)

Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 85(Granted Patents)

Location History:

Bures sur Yvette, FR (2000 - 2017)
Les Ulis, FR (2019 - 2022)

Company Filing History:

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft

patents

7. 1 out of 47

Merck Patent Gesellschaft MIT

patents

8. 1 out of 100

Merck Patent Gesellschaft MIT Beschraenkter Haftung

patents

Years Active: 2000-2022

Loading Chart...

Areas of Expertise:

Tryptophan Metabolites

Muscle Atrophy

Insulin Secretion

Pyrazinone Derivatives

Quinoxalinone Derivatives

Benzofuran Derivatives

Dihydro-1,3,5-Triazine

Antidiabetic Compounds

Piperazine Derivatives

Pharmaceutical Compositions

Therapeutic Uses

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11369595 - Use of tryptophan metabolites for treating muscle atrophy (2022-06-28),

2. 10350184 - Derivatives used in the treatment of muscle atrophy (2019-07-16),

3. 9777015 - Useful thiophene derivatives in the treatment of diabetes (2017-10-03),

4. 9381191 - Imidazopyridine derivatives useful in treating diabetes (2016-07-05),

5. 9233937 - Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones (2016-01-12),

6. 9102632 - Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2015-08-11),

7. 8835634 - Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2014-09-16),

8. 8815859 - Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof (2014-08-26),

9. 8642617 - Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2014-02-04),

10. 8637522 - Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2014-01-28),

11. 8609689 - Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2013-12-17),

12. 8415352 - Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2013-04-09),

13. 8178556 - Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2012-05-15),

14. 7816397 - Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes (2010-10-19),

15. 7767676 - Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses (2010-08-03),

Title: **Micheline R Kergoat: Innovator in Muscle Atrophy Treatment**

Introduction

Micheline R Kergoat, based in Bures-sur-Yvette, France, is a prominent inventor with a remarkable portfolio of 25 patents. Her innovative work primarily focuses on the use of tryptophan metabolites and other derivatives for treating muscle atrophy, a critical health concern in various populations, particularly the elderly and athletes.

Latest Patents

Among her latest innovations is a patent that emphasizes the use of tryptophan metabolites, specifically kynurenic acid, anthranilic acid, quinolinic acid, picolinic acid, and quinaldic acid. This invention targets the treatment of muscle atrophy, leveraging these metabolites to enhance or maintain muscle mass and strength in mammals. The solution aims to combat muscle loss, prevent symptoms of sarcopenia, and support recovery after intense physical activities.

Another significant patent focuses on oxime and alkoxy derivatives, designed for the treatment and prevention of muscle atrophy. This approach highlights their potential to limit muscle deterioration and bolster muscle growth in exercising mammals, thereby addressing age-related issues and the repercussions of immobility or medical treatment.

Career Highlights

Micheline has collaborated with notable organizations in her field, such as Merck Patent GmbH and Metabrain Research. Her work has significantly influenced advancements in the medical use of tryptophan and its derivatives, making her a key player in the realm of pharmaceutical innovations aimed at enhancing muscle health.

Collaborations

Throughout her career, Micheline R Kergoat has worked alongside esteemed colleagues, including Christine G Charon and Samer Elbawab. These collaborations have spurred innovative research and development in the medical field, further amplifying the impact of her patented inventions.

Conclusion

Micheline R Kergoat stands out as an influential inventor dedicated to tackling the challenges of muscle atrophy through her innovative patents. Her contributions not only benefit individuals facing muscle deterioration but also pave the way for future research and advancements in the field of muscle health.

Profile summary based on public USPTO records.